Answers are grounded in this paper and cite their sources.
Objectives Primary: explore whether a single session of virtual reality (VR) was associated with reduced self-reported pain in people with advanced cancer. Secondary: describe baseline quality of life, symptom burden and pain interference; compare change in pain between hospice and hospital settings and describe acceptability and safety. Methods Single-arm pre–post study at four UK sites (two hospices, two hospitals). Adults with advanced cancer and pain in the past week were eligible. Participants completed the Brief Pain Inventory, EQ-5D-5 L, and EORTC QLQ-C30 before VR. They rated current pain (0-10) immediately before and after the session. A Wilcoxon signed-rank test assessed change. Results Thirty-seven participants were recruited (hospice n = 19, hospital n = 18; median age 60; 65% female). Baseline symptom burden was high: QLQ-C30 fatigue and pain scores approached the scale maximum, and mean EQ-5D index was 0.34. Pain reduced from a median of 4 to 2 (z = 3.67, P < 0.001, r = 0.60). Nineteen (51%) reported a reduction, 10 (27%) by ≥ 2 points. Reductions were observed in hospice ( P = 0.003) and hospital ( P = 0.024) settings, with no evidence of a difference between them ( P = 0.452). No serious adverse events occurred. Conclusions A single VR session was well tolerated and associated with reduced self-reported pain, with early signals of similar effects across care settings. VR may offer a low-risk, non-pharmacological adjunct within multimodal pain management. Controlled trials are needed to establish efficacy, duration of effect and which patients benefit most.
No takes yet. Share an insight, caveat, or question.
White et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: